This site is for informational purposes only and does not provide medical advice, diagnosis, or treatment. Always consult your healthcare provider.
IL-15 Superagonist With or Without Vaccine in Biochemically Recurrent Prostate Cancer After Previous Stereotactic Body Radiation Therapy | MicrobiomeTrials
← Back to trials NCT07686380
IL-15 Superagonist With or Without Vaccine in Biochemically Recurrent Prostate Cancer After Previous Stereotactic Body Radiation Therapy Recruiting PHASE2 INTERVENTIONAL
Read the full scientific description See full eligibility requirements Trial Details Start: 2026-09-16Est. Completion: 2029-01-30
Enrollment target: 65 participantsLocations National Institutes of Health Clinical Center, Bethesda, Maryland, United States Other microbiome trials you might be interested in Prostate Cancer Recurrent Prostate Cancer Metastatic Prostate Cancer Prostate Cancer Recurrent Prostate Cancer Metastatic
This is a randomized, open-label, pilot study assessing the impact of a short course of bicalutamide on PSMA expression …
St Louis, United States Est. completion Nov 14, 2027
Adenocarcinoma of the Prostate Bone Metastases Hormone-resistant Prostate Cancer
Recurrent Prostate Cancer
Soft Tissue Metastases
Stage IV Prostate Cancer
This randomized phase II trial studies how well giving sipuleucel-T with or without radiation therapy works in treating …
Duarte, United States Completed Dec 31, 2018